Shares of Guardant Health Inc (NASDAQ:GH) have earned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $110.80.
Several analysts have commented on GH shares. ValuEngine lowered shares of Guardant Health from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Citigroup started coverage on shares of Guardant Health in a research report on Monday, January 6th. They issued a “buy” rating and a $100.00 price objective on the stock. Zacks Investment Research lowered shares of Guardant Health from a “buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Canaccord Genuity reaffirmed a “buy” rating and issued a $125.00 price objective on shares of Guardant Health in a research report on Friday, November 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research report on Friday, November 8th.
In other Guardant Health news, VP Timothy P. Eckersley sold 2,364 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.24, for a total value of $279,519.36. Also, Director Ian T. Clark sold 2,690 shares of the business’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $77.87, for a total transaction of $209,470.30. Following the completion of the transaction, the director now directly owns 3,992 shares of the company’s stock, valued at approximately $310,857.04. The disclosure for this sale can be found here. In the last three months, insiders sold 207,658 shares of company stock valued at $16,355,976. Corporate insiders own 13.00% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Griffin Asset Management Inc. boosted its stake in shares of Guardant Health by 1.4% in the 2nd quarter. Griffin Asset Management Inc. now owns 11,336 shares of the company’s stock valued at $979,000 after purchasing an additional 154 shares in the last quarter. Great West Life Assurance Co. Can boosted its stake in shares of Guardant Health by 6.8% in the 3rd quarter. Great West Life Assurance Co. Can now owns 2,562 shares of the company’s stock valued at $164,000 after purchasing an additional 163 shares in the last quarter. SeaCrest Wealth Management LLC boosted its stake in shares of Guardant Health by 2.3% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 9,892 shares of the company’s stock valued at $631,000 after purchasing an additional 220 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of Guardant Health by 0.4% in the 1st quarter. First Trust Advisors LP now owns 71,871 shares of the company’s stock valued at $5,513,000 after purchasing an additional 264 shares in the last quarter. Finally, HM Payson & Co. purchased a new stake in shares of Guardant Health in the 2nd quarter valued at $43,000. 78.22% of the stock is owned by institutional investors.
Shares of GH traded up $1.25 during trading hours on Friday, reaching $84.60. 1,622,277 shares of the stock traded hands, compared to its average volume of 818,000. The stock has a fifty day simple moving average of $78.18 and a 200 day simple moving average of $80.27. Guardant Health has a 52 week low of $38.71 and a 52 week high of $112.21.
Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.25. Guardant Health had a negative net margin of 40.99% and a negative return on equity of 11.70%. The company had revenue of $60.85 million for the quarter, compared to analyst estimates of $45.40 million. During the same period last year, the firm earned ($1.94) earnings per share. The firm’s revenue was up 180.4% on a year-over-year basis. On average, equities research analysts expect that Guardant Health will post -0.88 earnings per share for the current year.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Further Reading: What is a portfolio manager?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.